Chronic obstructive pulmonary disease: towards pharmacogenetics

Chronic obstructive pulmonary disease (COPD) is a common problem worldwide, and it is recognized that the term encompasses overlapping sub-phenotypes of disease. The development of a sub-phenotype may be determined in part by an individual's genetics, which in turn may determine response to tre...

Full description

Saved in:
Bibliographic Details
Published in:Genome medicine 2009-11, Vol.1 (113)
Main Authors: Tan, See Ling, Stockley, Robert A, Wood, Alice M
Format: Article
Language:English
Subjects:
Chronic obstructive lung disease
Development and progression
Pharmacogenomics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 113
container_start_page
container_title Genome medicine
container_volume 1
creator Tan, See Ling
Stockley, Robert A
Wood, Alice M
description Chronic obstructive pulmonary disease (COPD) is a common problem worldwide, and it is recognized that the term encompasses overlapping sub-phenotypes of disease. The development of a sub-phenotype may be determined in part by an individual's genetics, which in turn may determine response to treatment. A growing understanding of the genetic factors that predispose to COPD and its sub-phenotypes and the pathophysiology of the condition is now leading to the suggestion of individualized therapy based on the patients' clinical phenotype and genotype. Pharmacogenetics is the study of variations in treatment response according to genotype and is perhaps the next direction for genetic research in COPD. Here, we consider how knowledge of the pathophysiology and genetic risk factors for COPD may inform future management strategies for affected individuals.
format article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_healthsolutions_A454280526</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A454280526</galeid><sourcerecordid>A454280526</sourcerecordid><originalsourceid>FETCH-gale_healthsolutions_A4542805263</originalsourceid><addsrcrecordid>eNqNyr0OgjAUQOHGaCL-vEMnNxLEAuJiDNH4AA5u5FqutKa0pLdofHsXB0en8w1nxKJ1keVxWYrr-MdTNiN6JEkuUlFEbF8p76yW3N0o-EEG_UTeD6ZzFvybN5oQCHc8uBf4hnivwHcgXYsWg5a0YJM7GMLlt3O2Oh0v1TluwWCtEExQ5MwQtLNUH0Qm0m2Spfnm7_EDNRY9uQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Chronic obstructive pulmonary disease: towards pharmacogenetics</title><source>PubMed Central</source><creator>Tan, See Ling ; Stockley, Robert A ; Wood, Alice M</creator><creatorcontrib>Tan, See Ling ; Stockley, Robert A ; Wood, Alice M</creatorcontrib><description>Chronic obstructive pulmonary disease (COPD) is a common problem worldwide, and it is recognized that the term encompasses overlapping sub-phenotypes of disease. The development of a sub-phenotype may be determined in part by an individual's genetics, which in turn may determine response to treatment. A growing understanding of the genetic factors that predispose to COPD and its sub-phenotypes and the pathophysiology of the condition is now leading to the suggestion of individualized therapy based on the patients' clinical phenotype and genotype. Pharmacogenetics is the study of variations in treatment response according to genotype and is perhaps the next direction for genetic research in COPD. Here, we consider how knowledge of the pathophysiology and genetic risk factors for COPD may inform future management strategies for affected individuals.</description><identifier>ISSN: 1756-994X</identifier><identifier>EISSN: 1756-994X</identifier><language>eng</language><publisher>BioMed Central Ltd</publisher><subject>Chronic obstructive lung disease ; Development and progression ; Pharmacogenomics</subject><ispartof>Genome medicine, 2009-11, Vol.1 (113)</ispartof><rights>COPYRIGHT 2009 BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790</link.rule.ids></links><search><creatorcontrib>Tan, See Ling</creatorcontrib><creatorcontrib>Stockley, Robert A</creatorcontrib><creatorcontrib>Wood, Alice M</creatorcontrib><title>Chronic obstructive pulmonary disease: towards pharmacogenetics</title><title>Genome medicine</title><description>Chronic obstructive pulmonary disease (COPD) is a common problem worldwide, and it is recognized that the term encompasses overlapping sub-phenotypes of disease. The development of a sub-phenotype may be determined in part by an individual's genetics, which in turn may determine response to treatment. A growing understanding of the genetic factors that predispose to COPD and its sub-phenotypes and the pathophysiology of the condition is now leading to the suggestion of individualized therapy based on the patients' clinical phenotype and genotype. Pharmacogenetics is the study of variations in treatment response according to genotype and is perhaps the next direction for genetic research in COPD. Here, we consider how knowledge of the pathophysiology and genetic risk factors for COPD may inform future management strategies for affected individuals.</description><subject>Chronic obstructive lung disease</subject><subject>Development and progression</subject><subject>Pharmacogenomics</subject><issn>1756-994X</issn><issn>1756-994X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqNyr0OgjAUQOHGaCL-vEMnNxLEAuJiDNH4AA5u5FqutKa0pLdofHsXB0en8w1nxKJ1keVxWYrr-MdTNiN6JEkuUlFEbF8p76yW3N0o-EEG_UTeD6ZzFvybN5oQCHc8uBf4hnivwHcgXYsWg5a0YJM7GMLlt3O2Oh0v1TluwWCtEExQ5MwQtLNUH0Qm0m2Spfnm7_EDNRY9uQ</recordid><startdate>20091130</startdate><enddate>20091130</enddate><creator>Tan, See Ling</creator><creator>Stockley, Robert A</creator><creator>Wood, Alice M</creator><general>BioMed Central Ltd</general><scope/></search><sort><creationdate>20091130</creationdate><title>Chronic obstructive pulmonary disease: towards pharmacogenetics</title><author>Tan, See Ling ; Stockley, Robert A ; Wood, Alice M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-gale_healthsolutions_A4542805263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Chronic obstructive lung disease</topic><topic>Development and progression</topic><topic>Pharmacogenomics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tan, See Ling</creatorcontrib><creatorcontrib>Stockley, Robert A</creatorcontrib><creatorcontrib>Wood, Alice M</creatorcontrib><jtitle>Genome medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tan, See Ling</au><au>Stockley, Robert A</au><au>Wood, Alice M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic obstructive pulmonary disease: towards pharmacogenetics</atitle><jtitle>Genome medicine</jtitle><date>2009-11-30</date><risdate>2009</risdate><volume>1</volume><issue>113</issue><issn>1756-994X</issn><eissn>1756-994X</eissn><abstract>Chronic obstructive pulmonary disease (COPD) is a common problem worldwide, and it is recognized that the term encompasses overlapping sub-phenotypes of disease. The development of a sub-phenotype may be determined in part by an individual's genetics, which in turn may determine response to treatment. A growing understanding of the genetic factors that predispose to COPD and its sub-phenotypes and the pathophysiology of the condition is now leading to the suggestion of individualized therapy based on the patients' clinical phenotype and genotype. Pharmacogenetics is the study of variations in treatment response according to genotype and is perhaps the next direction for genetic research in COPD. Here, we consider how knowledge of the pathophysiology and genetic risk factors for COPD may inform future management strategies for affected individuals.</abstract><pub>BioMed Central Ltd</pub></addata></record>
fulltext fulltext
identifier ISSN: 1756-994X
ispartof Genome medicine, 2009-11, Vol.1 (113)
issn 1756-994X
1756-994X
language eng
recordid cdi_gale_healthsolutions_A454280526
source PubMed Central
subjects Chronic obstructive lung disease
Development and progression
Pharmacogenomics
title Chronic obstructive pulmonary disease: towards pharmacogenetics
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T12%3A22%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20obstructive%20pulmonary%20disease:%20towards%20pharmacogenetics&rft.jtitle=Genome%20medicine&rft.au=Tan,%20See%20Ling&rft.date=2009-11-30&rft.volume=1&rft.issue=113&rft.issn=1756-994X&rft.eissn=1756-994X&rft_id=info:doi/&rft_dat=%3Cgale%3EA454280526%3C/gale%3E%3Cgrp_id%3Ecdi_FETCH-gale_healthsolutions_A4542805263%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A454280526&rfr_iscdi=true